Concepedia

Eser Adiguzel

EA

5

Publications

126

Citations

5

H-Index

2022

Active since

Affiliations

Novartis (United States)(Current)

Retina Consultants of Texas

University of California, Los Angeles

Rutgers, The State University of New Jersey

Doheny Eye Institute

Eser Adiguzel is an author at Novartis (United States) specializing in glaucoma, ophthalmology, and medicine.

ORCID

Top concepts

Publications per year

2022–2024

5

Publications

5

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Arshad M. Khanani, David M. Brown, Glenn J. Jaffe et al. · Ophthalmology · 2022 · 69 citations

, , +8

One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry

Mathew W. MacCumber, Charles C. Wykoff, Hélène Karcher et al. · Ophthalmology · 2023 · 18 citations

, , +7

Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry

Marco A. Zarbin, Mathew W. MacCumber, Hélène Karcher et al. · Ophthalmology and Therapy · 2024 · 15 citations · Full text

Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab

Mathew W. MacCumber, Charles C. Wykoff, Hélène Karcher et al. · Ophthalmology · 2023 · 12 citations

MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

David M. Brown, Glenn J. Jaffe, Charles C. Wykoff et al. · Ophthalmology · 2024 · 12 citations · Full text

Rows per page

1–5 of 5